GLAXOSMITHKLINE SUES MODERNA FOR US PATENT INFRINGEMENT OVER COVID VACCINES.
British drugmaker GlaxoSmithKline (GLAX.NS), opens new tab sued Moderna (MRNA.O), opens new tab in U.S. federal court in Delaware on Tuesday, accusing its American rival of violating GSK’s patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.
According to the two lawsuits, opens new tab, Moderna’s lipid nanoparticles for transporting fragile mRNA into the human body infringe several GSK patents covering similar innovations. GSK filed a related lawsuit against Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab in the same court in April over their COVID-19 vaccine. The new litigation seeks unspecified monetary damages.A Moderna spokesperson said the company was aware of the new litigation and would defend itself against the claims. A GSK spokesperson said the drugmaker is “willing to license these patents on commercially reasonable terms and to ensure continued patient access.
The lawsuits add to a web of U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their vaccines, including one brought by Moderna against Pfizer in 2022.
Information taken from Reuters.
#Reuters
Spanish 
English